Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 110Magnetic Resonance Spectroscopy 87Biopsy 56pembrolizumab 53Carboplatin 52Cisplatin 49Nivolumab 45Radiotherapy 37Cyclophosphamide 37Paclitaxel 34Gemcitabine 33Radiation 29Dexamethasone 29Bevacizumab 29atezolizumab 27Pemetrexed 26Etoposide 25X-Rays 22Vincristine 22Prednisone 22Lenalidomide 22Immunoglobulin G 22Doxorubicin 22Disulfides 22venetoclax 21olaparib 21Leucovorin 21Rituximab 20Fluorouracil 20Taxes 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × RC48 antibody × 30 days × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡